GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sana Biotechnology Inc (NAS:SANA) » Definitions » Cash Flow from Operations

Sana Biotechnology (Sana Biotechnology) Cash Flow from Operations

: $-253.58 Mil (TTM As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, Sana Biotechnology's Net Income From Continuing Operations was $-88.12 Mil. Its Depreciation, Depletion and Amortization was $11.26 Mil. Its Change In Working Capital was $10.24 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $7.93 Mil. And its Cash Flow from Others was $6.72 Mil. In all, Sana Biotechnology's Cash Flow from Operations for the three months ended in Dec. 2023 was $-51.96 Mil.


Sana Biotechnology Cash Flow from Operations Historical Data

The historical data trend for Sana Biotechnology's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sana Biotechnology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Premium Member Only -85.52 -137.98 -251.05 -290.05 -253.58

Sana Biotechnology Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.07 -79.27 -58.80 -63.55 -51.96

Sana Biotechnology Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Sana Biotechnology's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Sana Biotechnology's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-253.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sana Biotechnology  (NAS:SANA) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Sana Biotechnology's net income from continuing operations for the three months ended in Dec. 2023 was $-88.12 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Sana Biotechnology's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $11.26 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Sana Biotechnology's change in working capital for the three months ended in Dec. 2023 was $10.24 Mil. It means Sana Biotechnology's working capital increased by $10.24 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Sana Biotechnology's cash flow from deferred tax for the three months ended in Dec. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Sana Biotechnology's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Sana Biotechnology's asset impairment charge for the three months ended in Dec. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Sana Biotechnology's stock based compensation for the three months ended in Dec. 2023 was $7.93 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Sana Biotechnology's cash flow from others for the three months ended in Dec. 2023 was $6.72 Mil.


Sana Biotechnology Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Sana Biotechnology's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Sana Biotechnology (Sana Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.
Executives
Christian Hordo officer: SVP, Chief Business Officer C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Douglas E Williams officer: EVP & President, R&D C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Bernard J Cassidy officer: EVP & General Counsel C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
James J. Macdonald officer: See Remarks C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Sunil Agarwal officer: See Remarks 60 LEVERONI COURT, NOVATO CA 94949
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship V Venturelabs Rx Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Venturelabs V Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arch Venture Fund Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Sana Biotechnology (Sana Biotechnology) Headlines

From GuruFocus

Sana Biotechnology to Host Research & Development Day

By sperokesalga sperokesalga 04-24-2023

Sana Biotechnology to Present at June 2023 Investor Conferences

By sperokesalga sperokesalga 05-31-2023